bexarotene has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, DJ; Chu, Y; Huang, CK; Kang, K; Lin, JX; Lin, XY; Wu, MX; Xu, CS; Zhang, GS; Zhang, HL; Zhu, J | 1 |
| Chai, D; Lin, J; Lin, X; Liu, J; Ruan, Q; Xie, H; Xu, C; Zeng, J; Zheng, Q | 1 |
2 other study(ies) available for bexarotene and Cirrhosis
| Article | Year |
|---|---|
Retinoid X receptor agonists alleviate fibroblast activation and post-infarction cardiac remodeling via inhibition of TGF-β1/Smad pathway.
Topics: Animals; Bexarotene; Cardiomyopathies; Fibroblasts; Fibrosis; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Retinoid X Receptors; Transforming Growth Factor beta1; Ventricular Remodeling | 2023 |
Retinoid X receptor agonists attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes through LKB1-dependent anti-fibrosis effects.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Bexarotene; Cardiomyopathies; Diabetes Mellitus, Type 1; Fibrosis; Humans; Male; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Retinoid X Receptors; Ribosomal Protein S6 Kinases, 70-kDa; Streptozocin | 2020 |